Cipaglucosidase alfa with miglustat in the treatment of late-onset Pompe disease: Early Access to Medicines scheme (EAMS)

Cipaglucosidase alfa with miglustat has been approved by the MHRA for availability via the EAMS for the treatment of late-onset Pompe disease. The scientific opinion includes a Public Assessment Report, treatment protocol and information summaries for HCPs and patients.

Source:

Medicines and Healthcare products Regulatory Agency